MustafaSSiddiquiMDFAAN

Movement Disorder

Professor of Neurology & Neurosurgery, Wake Forest School of Medicine. Division Head Movement Disorders Atrium Health Wake Forest Baptist

Join to view full profile

Dr. Siddiqui is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Siddiqui's full profile

Already have an account?

Office
Medical Center Blvd
Wake Forest Baptist Medical Center
Winston Salem, NC 27157
Phone+1 336-716-4101

Fax+1 336-716-9489

Summary

Mustafa Saad Siddiqui, MD, is a Professor of Neurology & Neurosurgery at Wake Forest School of Medicine. He is Division Chief of Movement disorders and Co-Director of Deep Brain Stimulation (DBS) program at Atrium Health Wake Forest Baptist. He completed his Neurology residency from Drexel University, Philadelphia and Fellowship in Movement disorders and Deep Brain Stimulation from University of Florida, Gainesville.

He is Fellow of the American Neurological Association and the American Academy of Neurology. He is a member of the Parkinson's Disease Study Group (PSG). He is listed in Best Doctors in America and has been Principal investigator in many clinical trials for Parkinson’s disease including a trial on gene therapy.

He has published in peer reviewed journals such as Lancet Neurology, Neurology, Neurosurgery, Journal of Neurology, Stroke, Journal of Neurology Neurosurgery & Psychiatry, Stereotactic & Functional Neurosurgery and written many book chapters. Dr. Siddiqui's interests include Parkinson’s disease, tremors, dystonia, botulinum toxin therapy, movement disorders, cognitive neuroscience and deep brain stimulation.

Clinical Expertise

Deep brain stimulation, Torticollis, Brain mapping, Dystonia, Parkinson's disease, Essential tremor, General neurology, Botulinum toxin injections for spasticity, Botulinum toxin injections for movement disorders, Benign essential blepharospasm, Spasmodic torticollis, Blepharospasm

Education & Training

University of FloridaFellowship, Neuromuscular Medicine (Neurology), 2005 - 2006
Drexel University College of Medicine/Hahnemann University HospitalResidency, Neurology, 2002 - 2005
Lincoln Medical and Mental Health CenterInternship, Internal Medicine, 2001 - 2002
Army Medical College Quaid-e-Azam UnivClass of 1989

Certifications & Licensure

NC State Medical License 2006 - 2025
PA State Medical License 2002 - 2005
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Best Doctors of America
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Start of enrollment: 2009 Jan 01
Completed
Phase 3
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease Start of enrollment: 2007 Jul 01
Terminated
Phase 3
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Start of enrollment: 2008 Jan 01
Completed
Phase 3
Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease Start of enrollment: 2008 Aug 01
Terminated
Phase 2
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Start of enrollment: 2009 Nov 13
Completed
Phase 3
The Dystonia Coalition Natural History and Biospecimen Repository for Isolated Dystonias Start of enrollment: 2011 Jan 01
Completed
Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease Start of enrollment: 2013 May 17
Completed
Not Applicable
SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) Start of enrollment: 2014 Dec 22
Completed
Phase 2
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease Start of enrollment: 2015 Jun 18
Completed
Phase 3
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease Start of enrollment: 2015 Aug 31
Completed
Phase 3
Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease Start of enrollment: 2016 Jan 04
Completed
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) Start of enrollment: 2017 Nov 09
Completed
Phase 2
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease Start of enrollment: 2018 Jan 10
Terminated
Phase 2
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 Start of enrollment: 2019 Feb 18
Active, not recruiting
Phase 2
Wearable Assessments in the Clinic and Home in PD Start of enrollment: 2019 Apr 24
Completed
Trial of Parkinson's And Zoledronic Acid Start of enrollment: 2019 Nov 15
Recruiting
Phase 4
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Fine-tuning the brain: The role of local field potentials in DBS programming.
Mustafa S Siddiqui, Zoltan Mari
Parkinsonism & Related Disorders. 2024-08-01
Subjective feelings associated with expectations and rewards during risky decision-making in impulse control disorder.
Brittany Liebenow, Angela Jiang, Emily K DiMarco, L Paul Sands, Mary Moya-Mendez
Scientific Reports. 2024-03-04
Time perception reflects individual differences in motor and non-motor symptoms of Parkinson's disease.
Emily K DiMarco, Renata Sadibolova, Angela Jiang, Brittany Liebenow, Rachel E Jones
Parkinsonism & Related Disorders. 2023-09-01

Press Mentions

New Form of Drug Helps Some Parkinson’s PatientsApril 29th, 2016
A Flood of Emotions: Treating the Uncontrollable Crying and Laughing of Pseudobulbar AffectMarch 28th, 2012
Boston Scientific Receives FDA Approval for Innovative Deep Brain Stimulation SoftwareJuly 27th, 2023
Join now to see all